Merck to evaluate Vaxxas' new skin-patch vaccine delivery platform
This article was originally published in Scrip
Vaxxas, a young biotech company with a novel vaccine delivery platform, has begun a research collaboration with Merck & Co. The big pharma will evaluate Cambridge, MA-based Vaxxas' Nanopatch technology that induces an immune reaction by targeting vaccines to immune cells immediately below the surface of the skin.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.